Nagler, Arnon and Ngoya, Maud and Galimard, Jacques-Emmanuel and Labopin, Myriam and Bornhaeuser, Martin and Stelljes, Matthias and Finke, Juergen and Ganser, Arnold and Einsele, Herman and Kroeger, Nicolaus and Brecht, Arne and Bethge, Wolfgang and Edinger, Matthias and Kulagin, Aleksandr and Passweg, Jakob and Blau, Igor Wolfgang and Elmaagacli, Ahmet and Schaefer-Eckart, Kerstin and Platzbecker, Uwe and Schroeder, Thomas and Bunjes, Donald and Tischer, Johanna and Martin, Sonja and Spyridonidis, Alexandros and Giebel, Sebastian and Savani, Bipin and Mohty, Mohamad (2022) Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis. CLINICAL CANCER RESEARCH, 28 (19). pp. 4258-4266. ISSN 1078-0432, 1557-3265
Full text not available from this repository. (Request a copy)Abstract
Purpose: We evaluated outcomes of unrelated transplantation for primary refractory/relapsed (ref/rel) acute myeloid leukemia (AML), comparing two cohorts according to the year of transplant, 2000-2009 and 2010-2019.Patients and Methods: Multivariable analyses were performed using the Cox proportional-hazards regression model.Results: 3,430 patients were included; 876 underwent a trans-plant between 2000-2009 and 2554 in 2010-2019. Median follow-up was 8.7 (95% CI, 7.8-9.4) and 3.4 (95% CI, 3.1-3.6) years (P < 0.001). Median age was 52 (18-77) and 56 (18-79) years (P > 0.0001); 45.5% and 55.5% had refractory AML while 54.5% and 44.5% had relapsed AML. Conditioning was myeloablative in 60% and 52%, respectively. Neutrophil recovery and day 100 incidence of acute and 2-year incidence of chronic graft-versus-host disease (GvHD) were similar between the two periods. Two-year relapse incidence was higher for patients undergoing transplant in the 2000-2009 period versus those undergoing transplant in 2010- 2019: 50.2% versus 45.1% (HR, 0.85; 95% CI, 0.74-0.97; P = 0.002). Leukemia-free survival; overall survival; and GvHD-free, relapse-free survival were lower for the 2000-2009 period: 26% versus 32.1% (HR, 0.87; 95% CI, 0.78-0.97; P = 0.01), 32.1% versus 38.1% (HR, 0.86; 95% CI, 0.77-0.96; P = 0.01), and 21.5% versus 25.3% (HR, 0.89; 95% CI, 0.81-0.99; P = 0.03), respectively. Two-year non-relapse mortality was not significantly different (23.8% vs. 23.7%; HR, 0.91; 95% CI, 0.76-1.11; P = 0.34).Conclusions: Outcome of unrelated transplantation for patients with ref/rel AML has improved in the last two decades, rescuing about one third of the patients.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | VERSUS-HOST-DISEASE; RETROSPECTIVE ANALYSIS; AML; SURVIVAL; RELAPSE; ADULTS; BLOOD; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 12 Dec 2023 14:20 |
| Last Modified: | 12 Dec 2023 14:20 |
| URI: | https://pred.uni-regensburg.de/id/eprint/58737 |
Actions (login required)
 |
View Item |
